Immunicum AB
Immunicum AB (publ) Plans to Expand its Research and Process Development Facilities in Leiden, the Netherlands
Press Release
27 January 2021
Immunicum AB (publ) Plans to Expand its Research and Process Development Facilities in Leiden, the Netherlands
Immunicum AB (publ; IMMU.ST) announced today that its in-house research and process development activities will move into a new facility at the Leiden Bio Science Park, the Netherlands. The Company has signed a long-term lease with developer Kadans Science Partner for approximately 1,100 square meters of laboratory and office space in the Plus Ultra Leiden, a new building currently under development. Furthermore, Immunicum has the option to rent an additional 1,100 square meters to further support its future growth. The new location, that is expected to be fully commissioned in 2022, will serve as Immunicum’s core research and development hub.
"This state-of-the-art facility in one of Europe’s most vibrant life sciences research communities is an integral part of our corporate strategy as it will enable us to rapidly and cost-effectively continue the development of potential transformative treatment options for cancer patients," stated Sven Rohmann, M.D., Ph.D., CEO of Immunicum. "Following the combination with DCprime, we have strengthened our team of leading experts and we will establish this new facility as a center of excellence, thereby gaining full control over crucial product development aspects of our cell-based therapies."
The new facility will house the entire Leiden-based operation of Immunicum. Multiple laboratory suites will support Immunicum’s research and development activities for the now expanded pipeline of next-generation cell-based immunotherapies following the business combination announced in December last year.
For more information, please contact:
Sven Rohmann, M.D., Ph.D., CEO
Telephone: +46 8 732 8400
E-mail: info@immunicum.com
INVESTOR RELATIONS
Jonas Rodny and Carolin Wiken
Paues Åberg Communications
Telephone: +46 76 190 90 51
E-mail: ir@immunicum.com
Media Relations
Eva Mulder and Sophia Hergenhan, Ph.D.
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com
About Immunicum AB (publ)
Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com
Attachment
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Kvika banki hf.25.2.2021 17:26:18 CET | Press release
Kvika banki hf.: Announcement regarding the exercising of subscription rights (warrants) and an increase in share capital
North Media A/S25.2.2021 17:16:18 CET | Press release
Disclosure of managers’ and closely related parties’ transactions with shares and/or linked financial instruments in North Media A/S
North Media A/S25.2.2021 17:16:07 CET | Pressemeddelelse
Offentliggørelse af ledende medarbejderes og disses nærtståendes transaktioner med aktier og/eller tilknyttede finansielle instrumenter i North Media A/S
DFDS A/S25.2.2021 17:12:37 CET | Press release
TRANSACTIONS IN DFDS A/S SHARES MADE BY EXECUTIVES
DFDS A/S25.2.2021 17:12:27 CET | Pressemeddelelse
TRANSAKTIONER I DFDS A/S AKTIER AF LEDELSEN
Solar A/S25.2.2021 16:43:45 CET | Press release
No. 7 Share trading in Solar A/S
Solar A/S25.2.2021 16:43:35 CET | Pressemeddelelse
Nr. 7 Aktiehandel i Solar A/S
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom